ABSTRACT
No abstract available.
Subject(s)
Humans , Male , Middle Aged , Carcinoid Tumor/diagnosis , Colonoscopy , Cysts/pathology , Rectal Neoplasms/diagnosis , Synaptophysin/metabolism , Tomography, X-Ray ComputedABSTRACT
According to the World Health Organization (WHO) classification system, cases with t(8;21)(q22;q22) should be diagnosed as acute myeloid leukemia (AML) even with a blast count of less than 20 percent in blood or bone marrow. It is an uncommon manifestation, moreover hypocellularity is rarely observed in this subtype of leukemia. Here, we report a case of t(8;21) in a patient with marked hypocellularity of less than 5 percent and a blast count of less than 20 percent. This patient responded relatively well to chemotherapy. An allogeneic bone marrow transplantation was performed with good engraftment . This case suggests that hypocellular AML with a t(8;21) has as good a prognosis as hypercellular AML with t(8;21).
Subject(s)
Humans , Bone Marrow , Bone Marrow Transplantation , Classification , Drug Therapy , Leukemia , Leukemia, Myeloid, Acute , Prognosis , World Health OrganizationABSTRACT
Pernicious anemia is the frequent cause of megaloblastic anemia, and it is the result of a vitamin B12 deficiency due to the decrease or absence of intrinsic factor (IF) because of gastric mucosa atrophy or autoimmune destruction of IF-producing parietal cells. With the existence of a severe gastric atrophy, there is a decreased in acid and IF production and a further change in vitamin B12 absorption. Mercury is ubiquitous in nature and exists in 3 forms, elemental mercury, inorganic salts and organic compounds. Organic forms, specifically methyl mercury, are the most toxic of the 3 classes of mercurials. Methyl mercury exerts its most devastating effect on the central nervous system by causing psychiatric disturbances, ataxia, visual loss, hearing loss, and neuropathy. We report a case of mercury intoxication associated with pernicious anemia. The 77 years old patient was referred to Yeungnam University Hospital for tongue pain, somatitis, headache and aggressive behavior. He had taken an unevaluated medicine for a long time. After clinical evaluation, this case was diagnosed as a pernicious anemia and the unevaluated medicine was made up of mercury. After the administration of D-penicillamine and intramuscular injection of BAL and cobalamine, clinical symptoms and aggressive behavior were improved as well as laboratory findings.
Subject(s)
Aged , Humans , Absorption , Anemia, Megaloblastic , Anemia, Pernicious , Ataxia , Atrophy , Central Nervous System , Gastric Mucosa , Headache , Hearing Loss , Injections, Intramuscular , Intrinsic Factor , Penicillamine , Rabeprazole , Salts , Tongue , Vitamin B 12 , Vitamin B 12 DeficiencyABSTRACT
The objective of this study was to review the natural history of extrapulmonary small cell carcinoma (EPSCC) with specific emphasis on clinical features, response to treatment and survival. The records of all patients (n=34) with EPSCC treated at Yeungnam University Medical Center and Catholic University of Daegu Medical Center between 1998 and 2005 were retrieved and reviewed. The primary sites of tumor were the esophagus and thymus in 6 patients (17.6%) each, pancreas and stomach in 5 patients each (14.7%); other sites included were the cervix, abdominal lymph nodes, abdominal wall, bladder, colon, maxillary sinus, nasal cavity, ovary, parotid gland and liver. Twenty three patients out of 34 had limited disease. The median survival of all patients was 14 months. Independent prognostic factors included stage and primary tumor location. The prognosis for the patients with extensive disease and in the gastrointestinal group was unfavorable. EPSCC is a non homogeneous disease entity. As a result of its frequent recurrence, multimodal therapy has a better outcome even in cases of limited disease. Combination chemotherapy plays a central role for treatment of extensive disease in EPSCC. Further multicenter studies are now needed to determine more details regarding disease sub-class and optimal treatment modality.
Subject(s)
Middle Aged , Male , Humans , Female , Aged, 80 and over , Aged , Adult , Thymus Neoplasms/mortality , Survival Rate , Stomach Neoplasms/mortality , Pancreatic Neoplasms/mortality , Esophageal Neoplasms/mortality , Combined Modality Therapy , Carcinoma, Small Cell/mortalityABSTRACT
BACKGROUND: Although many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained. We performed a prospective study on the combination chemotherapy of paclitaxel and cisplatin (PC). The primary objectives of the study were elucidating the disease response and evaluating the drug regimen's safety. METHODS: Patients with metastatic or recurrent gastric cancer received intravenous paclitaxel 175 mg/m2, and cisplatin 70 mg/m2 on day 1. This cycle was repeated every 3 weeks. RESULTS: From January 2000 to March 2004, 37 patients from 3 different hospitals were enrolled in this study. A total of 135 treatment cycles (median: 3 cycles) were administered. The responses were evaluable in 34 patients; 24 patients received this regimen as their first-line treatment for metastatic cancer and the other patients received it as their second-line treatment for recurrent cancer. The objective response rate (RR) was 26.5% (95% CI: 11.7-41.3) with two complete responses, and stable disease was observed in 41.1% of the patients. Importantly, an RR of 33.3% (95% CI: 0.6-66.0) was achieved for the eight patients who received this regimen as a first-line treatment. The median follow up duration was 14 months for all the patients, and the median time to progression was 6 months (95% CI: 1.9-10.2). The overall survival time was 8.9 months (95% CI: 7.0-11.0) with a 1-year survival rate of 18.7% (95% CI: 5.6-31.8). The most common toxicity was neutropenia. CONCLUSION: PC exhibited promising activity against gastric cancer for the previously untreated patients as a first-line treatment with an acceptable toxicity profile.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Cisplatin/therapeutic use , Drug Therapy, Combination , Follow-Up Studies , Neoplasm Metastasis/drug therapy , Neoplasm Recurrence, Local/drug therapy , Paclitaxel/therapeutic use , Prospective Studies , Safety , Stomach Neoplasms/drug therapy , Treatment OutcomeABSTRACT
We made clinical and statistical observation of low birth weight infants who were delivered at Keimyung University hospital during the 2 years and 4 months period from March, 1979 through July, 1981. The results obtained were as follows: 1) The sex ratio for live birth infants, male to female, was 1.28:1, and low-birth-weight infants was 0.96:1. The incidence of low birth weight infants was 66.5 per 1,000 live births. 2) The etiology of low-birth-weight infants, in order of frequency was: 1st, multiple pregncy, 2nd , permature ruptupe of membrane, 3rd, toxemia, 4th malposition of fotus and 5th , plaoente previa and abruptio placents. 3) The mortality rate for low-birth-weight infants was 123.5/1,000 low-birth-weight infants. 4) Premature percentage of low-birth-weight infants was 61.7%. 5) A sharp decrease in mortality rate was observed when infants weight over 1,750 grams at birth, and over 35 weeks gestation period. Therefore delayed delivery was recommendec. 6) Of all deaths of low-birth-weight infants in the nuracry, 85.9% died within 24 hours of birth, and 82.9% within 48 hours of birth. 7) There was no difference between male and female infants regarding mean helight, mean head circumference and mena chest cincumference according to weight.
Subject(s)
Female , Humans , Infant , Infant, Newborn , Male , Pregnancy , Head , Incidence , Infant, Low Birth Weight , Live Birth , Membranes , Mortality , Parturition , Sex Ratio , Thorax , ToxemiaABSTRACT
We made clinical and statistical observation of low birth weight infants who were delivered at Keimyung University hospital during the 2 years and 4 months period from March, 1979 through July, 1981. The results obtained were as follows: 1) The sex ratio for live birth infants, male to female, was 1.28:1, and low-birth-weight infants was 0.96:1. The incidence of low birth weight infants was 66.5 per 1,000 live births. 2) The etiology of low-birth-weight infants, in order of frequency was: 1st, multiple pregncy, 2nd , permature ruptupe of membrane, 3rd, toxemia, 4th malposition of fotus and 5th , plaoente previa and abruptio placents. 3) The mortality rate for low-birth-weight infants was 123.5/1,000 low-birth-weight infants. 4) Premature percentage of low-birth-weight infants was 61.7%. 5) A sharp decrease in mortality rate was observed when infants weight over 1,750 grams at birth, and over 35 weeks gestation period. Therefore delayed delivery was recommendec. 6) Of all deaths of low-birth-weight infants in the nuracry, 85.9% died within 24 hours of birth, and 82.9% within 48 hours of birth. 7) There was no difference between male and female infants regarding mean helight, mean head circumference and mena chest cincumference according to weight.